1. Home
  2. ATXG vs REVB Comparison

ATXG vs REVB Comparison

Compare ATXG & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ATXG

Addentax Group Corp.

HOLD

Current Price

$0.34

Market Cap

4.6M

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$2.01

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATXG
REVB
Founded
2014
2020
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ATXG
REVB
Price
$0.34
$2.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
62.5K
1.7M
Earning Date
02-13-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,141,952.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.78
52 Week High
$1.86
$55.20

Technical Indicators

Market Signals
Indicator
ATXG
REVB
Relative Strength Index (RSI) 39.52 72.98
Support Level $0.28 $1.78
Resistance Level $0.39 $2.32
Average True Range (ATR) 0.05 0.20
MACD -0.00 0.14
Stochastic Oscillator 31.39 84.32

Price Performance

Historical Comparison
ATXG
REVB

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: